Alzheimer's drug study yields positive results, say makers Eisai and Biogen
π§π΅πΆπ»πΈππΌππ. The Biogen/Eisai investigational Alzheimer's monoclonal antibody lecanemab achieved its main endpoint in a large clinical trial. With the FDA planning to review it in early January 2023, what will this drug mean for the treatment of Alzheimerβs disease?
